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Received July 12, 2011; accepted January 14, 2012AbstractBackground: To evaluate the efficacy and safety of administering a 3-month formulation of triptorelin as part of disease management of
Taiwanese men with advanced adenocarcinoma of the prostate.
Methods: Patients with newly diagnosed, locally advanced, or metastatic adenocarcinoma of the prostate were enrolled in our study, after
informed consent was obtained. All patients received bicalutamide 50 mg daily for 28 days, starting 7 days before the first injection of triptorelin.
A dosage of 11.25 mg triptorelin was injected on Day 0 (baseline) and repeated on Day 90. Prostate-specific antigen (PSA) and testosterone
concentrations were measured on Days 90 and 180.
Results: A total of 41 patients were enrolled, with a median age of 78 (57e92) years, and a baseline median PSA of 122.69 ng/mL. One patient
dropped out of the study, one was excluded in the fourth month due to a protocol violation, and one died 4 months after initiation of treatment as
a result of disease progression. In total, 40 men were eligible for Day 90 and 38 men for Day 180 analysis. On Day 90, 97.5% of men had
reached castration testosterone concentration 0.5 ng/mL, and all men had reached this concentration on Day 180. Serum PSA concentration
declined to 10.40  23.42 ng/mL on Day 90 ( p ¼ 0.0126) and 11.61  23.93 ng/mL on Day 180 ( p ¼ 0.0172). The most frequently seen
adverse event was gastrointestinal disturbance, including abdominal pain, diarrhea and constipation. Generally, adverse events were mild and
patient manageable.
Conclusion: Triptorelin 11.25 mg is effective in achieving medical castration and lowering PSA concentrations and can maintain its medicinal
effect for at least 90 days in Taiwanese men with advanced prostate cancer. This suggests that it can be an effective treatment for advanced
prostatic cancer.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Prostate cancer remains one of the most common cancers
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doi:10.1016/j.jcma.2012.04.010Western countries and lower in Asian countries, the incidence
of prostate cancer in Taiwan has increased dramatically in the
past 20 years. In 1996, prostate cancer was Taiwan’s the sixth
most commonly diagnosed cancer (8.58/100,000 per year),1,2
with an annual mortality rate of 2.19/100,000 in 1992,
increasing to 4.97/100,000 in 1999, and reaching 6.07/100,000
per year in 2001.3,4
Taiwanese men have increased their dietary fat consump-
tion in the last 20 years, which is believed to have contributed
to the rapid rise in the incidence of the disease. In addition, thehinese Medical Association. All rights reserved.
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introduction in 1988 is probably the main contributing factor
to the improved detection rate of prostate cancer. And further
challenging medical practitioners, approximately one-half of
all Taiwanese patients diagnosed with prostate cancer have
locally advanced or metastatic diseases (stage III and IV) upon
diagnosis.5
More than 65 years have passed since Huggins and
Hodges6,7 first treated men with prostate cancer with either
orchiectomy or estrogen and suggested the use of hormone
therapy for the management of advanced prostate cancer.
Subsequently, androgen deprivation was shown to be effective
in both delaying clinical progression and palliating symptoms
of metastatic disease, becoming a mainstay of treatment for
locally advanced and symptomatic metastatic disease.
Medical castration with gonadotropin-releasing hormone
(GnRH) agonists in prostate cancer patients was first reported
in 1982,8 a strategy which thereafter became the most
important approach for men with advanced prostate cancer.9
Long-term treatment with GnRH agonists leads to castration
levels of patient testosterone within three weeks of treatment
initiation. GnRH agonists usually cause a transitory rise in
serum testosterone over the first two weeks of therapy that
may cause tumor flare, resulting in an increase in pain and
serious side effects such as urethral obstruction and paralysis
in patients with extensive spinal column metastases.10 The
initial surge in testosterone can be controlled by an association
of an anti-androgen at initiation of the GnRH agonist.11
Randomized trials have shown that both surgical and chem-
ical androgen ablation have a similar impact on survival in
patients with stage IV PC.12
The hypothalamic luteinizing hormone-releasing hormone
(LHRH), also known as GnRH, was isolated and identified as
a decapeptide in Schally’s laboratory in 1971,13,14 and
subsequently synthesized by Guillemin and colleagues.15 It
controls the secretion of both gonadotropins from the pituitary
gland, with a short native GnRH associated half-life of just 2
to 4 minutes.
Triptorelin (D-Trp-6-LHRH) is a GnRH agonist in which
the glycine at position six has been replaced with D-trypto-
phan.16,17 This substitution enhances resistance to degradation
by endopeptidases, increases receptor binding affinity, and
results in a more potent analogue of GnRH. Acute adminis-
tration of triptorelin induces a rise of gonadotrophins lutei-
nizing hormone (LH) and follicle- stimulating hormone
(FSH), which in turn increases gonadal hormone production,
achieving the so-called “flare up” effect, whereas prolonged
administration of triptorelin results in down-regulation of the
GnRH receptors in the pituitary and decreased secretion of
luteinizing hormone. The outcome is a decreased production
of testosterone by Leydig cells. This chemical, reversible
castration is the basis for the use of GnRH analogues to treat
androgen dependent-cancers such as prostate cancer.
Pharmacokinetic studies show that, after a first plasma
surge occurring 2.5 to 3.6 hours after injection and a second
rise between Day 17 and Day 31, the mean triptorelin plasma
level is stable (0.03 to 0.06 ng/ml) and maintained until day91. Studies have shown the efficacy and safety of the monthly
injected form of triptorelin as well as the 3-month sustained
release form in advanced prostate carcinoma. Castration levels
of testosterone are obtained in the first weeks of treatment and
maintained in all patients for the duration of treatment. Trip-
torelin is an effective endocrine therapy for advanced prostate
carcinoma, avoiding the psychological impact of surgical
castration.18,19
In this study we investigated the effect of the sustained
release formulation of triptorelin (Diphereline prolonged
release (PR) 11.25 mg) on men from Taiwan with advanced
and metastatic prostate cancer.
2. Methods2.1. Study designThis was a multicenter and open labeled study designed to
investigate the efficacy and safety of three-month treatment
with Diphereline PR 11.25 mg in men with advanced prostatic
cancer in Taiwan. This open labeled study was passed through
each Internal Review Board, and then those patients also
signed informed consent before receiving treatment.2.2. Inclusion and exclusion criteriaInclusion criteria were de novo or untreated male patients
age  18 years; histologically-proven prostate cancer with
locally advanced or metastatic diseases amenable to
hormonal therapy; serum PSA levels  5 ng/ml; testosterone
concentration within the normal laboratory ranges, or
testosterone concentration lower than normal range but
higher than 0.5 ng/ml that investigator considered the subject
could be recruited for treatment (documented within 4 weeks
in advance of inclusion); life expectancy of more than nine
months; Eastern Cooperative Oncology Group (ECOG)
performance status  2; and informed consent in writing.
Exclusion criteria were previous surgical castration or low
testosterone levels (< 0.5 ng/ml); patient at risk of a serious
complication in the case of tumor flare (especially patients
having vertebral metastases with spinal cord compression or
with significant obstructive uropathy); previous administration
of a GnRH agonist, estrogens or anti androgens, concomitant
treatment with coumarin- or indanedione- derivatives;history
of hypersensitivity to GnRH analogues or to any of the
ingredients;patient having received an unlicensed drug, within
the last 30 days; any significant medical or psychiatric
condition that might prevent the patient from complying with
the study procedures; other known associated malignancy
(except curatively treated basal skin carcinoma); or patient
unwilling to comply fully with the protocol.2.3. Patient disease status at baselineFive patients in the intent-to-treat population had previ-
ously had surgery for advanced prostate cancer. Four patients
were classified as tumor, lymph node, and distant metastasis
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edition). Twenty-four patients had bone metastases.2.4. Hormone therapy protocolThe suspension of the drug was prepared immediately
before the intramuscular injection, according to the manu-
facturer’s instructions. All eligible patients received two
injections of triptorelin 11.25 mg on baseline and on Day 90,
and bicalutamide 50 mg once daily for 28 days starting 7 days
before the first injection of triptorelin 11.25 mg.2.5. Primary and secondary objectivesThe primary objective was to evaluate the efficacy of
triptorelin based on the percentage of patients with a testos-
terone concentration of 5 ng/ml on Day 90. The secondary
objectives were to investigate the effect of triptorelin on
clinical symptoms and quality of life; PSA concentrations on
Days 90 and 180; the development of bone metastases;
maintenance of castration based on percentage with testos-
terone concentrations 0.5 ng/ml on Day 180; efficacy of
triptorelin, based on the percentage of patients presenting with
testosterone concentrations0.2 ng/ml on Day 180; disease
progression on Day 180, and tolerability.2.6. AssessmentsTestosterone and PSA concentrations were measured on
Days 90 and 180. Clinical symptoms were recorded on Days 0,
90, and 180. Bone scintigraphy was used to assess bone
metastases at baseline and at the end of study (on Day 180).
Disease progression was measured either by the development
of new metastatic lesions in bone, or clinical evaluation during
the study period or death. To assess the effect of triptorelin on
quality of life, all men answered the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire QLQ-C30, version 3.0, a cancer-specific
questionnaire, at baseline and at the end of study.2.7. Safety evaluationAll adverse events were recorded by the patient or moni-
tored by the investigator throughout the study and were coded
using the 12th Quarter Medical Dictionary for Regulatory
Activities (MedDRA 12.0). On October 2009, International
Conference on Harmonisation (ICH) used MedDRA 12.0 to
application to adverse drug reaction/ adverse events & medical
and social history and indication.2.8. Statistical methods and analysisThree data sets (safety, intent-to-treat, per-protocol) were
introduced for statistical analysis. The safety population
consists of patients who had received at least one injection of
triptorelin at 11.25 mg. The intent-to-treat (ITT) population
consisted of patients who had received at least one dose oftriptorelin 11.25 mg and who provided any follow-up data for
one or more key efficacy variables. The per-protocol (PP)
population consists of patients who had received at least one
dose of triptorelin 11.25 mg and followed the protocol without
any major deviations.
The analyses of the safety data were performed based on the
safety population. The primary analysis based on the primary
efficacy endpoint, the percentage of patients presenting
a testosterone level 0.5 ng/ml on Day 90, was performed on
the ITT population. In addition, the PP population was per-
formed as secondary. Other analyses on the secondary efficacy
endpoints were performed on ITT and PP populations.
The primary and secondary efficacy analyses were per-
formed based on both the ITT and PP populations. The last-
observation-carried-forward (LOCF) approach was used to
evaluate missing data. All statistical tests were to be two-sided
which was evaluated at 5% level significance. As for the
dichotomous variables, the 95% confidence interval corre-
sponding to the incidence was calculated using Clopper-
Pearson method. For all continuous parameters, descriptive
statistics such as number of observations, mean, median,
standard deviation, minimum, maximum, upper and lower
quartile were calculated. The changes (and percentage
changes) from baseline at each evaluation time in the PSA
level were analyzed by using paired t-test. The number and
percentage of patients who experience adverse events were
summarized. Descriptive analysis of laboratory tests was
presented. The number and percentage of patients who
experience potentially clinically significant changes in labo-
ratory results, and those who discontinue, were also tabulated.
3. Results3.1. Patient selectionA total of 44 patients were screened from three medical
centers (Tri-Service General Hospital, Taipei Veterans General
Hospital, and Kaohsiung Veterans General Hospital, Taipei,
Taiwan, R.O.C.). The first patient was screened on February
19, 2008, and the last patient was screened on October 15,
2008. Three patients became ineligible after the screening
period; therefore, at total of 41 patients were treated with
triptorelin 11.25 mg. The last patient visit took place on April
8, 2009. Thirty-eight of the 41 patients (92.7%) completed the
6 month-study period (Fig. 1).3.2. Demographic and baseline characteristicsSummary statistics of demographic characteristics for all
patients of ITT (40 patients) and PP (38 patients) population
are listed in Table 1. Results in the PP population were similar
to the ITT population (Table 1).3.3. Disease characteristicsDetails of disease characteristics, including previous treat-
ment, classification, and bone metastasis sites, are summarized
Fig. 1. Flow diagram of patient progress through the trial.
258 C.-C. Kao et al. / Journal of the Chinese Medical Association 75 (2012) 255e261in Table 2. Among the ITT population, 5 of 40 (12.5%)
patients had previous surgical treatment for his their advanced
prostate cancer. Four patients were classified as Stage III and
36 patients as Stage IV. Twenty-four (60%) had bone metas-
tasis. Pelvis, ribs, and spinal column were the most frequent
sites of bone metastasis, followed by lower limbs, upper limbs
and skull (Table 2).3.4. EfficacyOn Day 90, 39 men (97.5%) had reduced their testosterone
concentration to  0.5 ng/ml, and all men had a testosteroneTable 1
Summary of demographic and baseline characteristics.
Characteristics ITT population PP population
n ¼ 40 n ¼ 38
Age (y) Mean  SD 77.4  8.0 77.4  8.0
Weight (kg) Mean  SD 63.4  9.6 62.9  9.6
Body mass
index (kg/m2)
Mean  SD 23.6  3.1 23.4  3.0
Testosterone
(ng/ml)
Mean  SD 3.13  1.68 3.17  1.72
Geometric mean 2.7 2.72
Serum PSA
(ng/ml)
Mean  SD 680.4  1636.8 684.2  1674.8
Geometric mean 122.7 121.2
FSH (mIU/ml) Mean  SD 18.11  14.28 18.51  14.52
Geometric mean 14.00 14.27
LH (mIU/ml) Mean  SD 16.99  18.62 17.59  18.92
Geometric mean 10.25 10.68
FSH ¼ follicle- stimulating hormone; ITT ¼ intent to treat; LH ¼ luteinizing
hormone; PP ¼ per-protocol; PSA ¼ prostate-specific antigen; SD ¼ standard
deviation.concentration of  0.5 ng/ml on Day 180 (Fig. 2). Twenty-
nine men (72%) had a testosterone concentration of
0.2e0.5 ng/ml on Day 90, and 30 men (75%) had a testos-
terone concentration of 0.2-0.5 ng/ml on Day 180. On both
Days 90 and 180, 10 men (25%) had a testosterone concen-
tration of  0.2 ng/ml.
Treatment with triptorelin reduced the median PSA
concentration from 122.69 ng/ml at baseline to
10.40  23.42 ng/ml on Day 90, and to 11.49  23.40 ng/ml
on Day 180 (Fig. 3). This amounts to a 99.2% (CI: 98.3e99.4)
reduction on Day 90 and a 99.2% (CI: 98.6e99.6) on Day 180.Table 2
Characteristics of the ITT population.
Characteristics ITT Population (n ¼ 40)
n %
Previous treatment for disease 5 12.5
TNM classification
Stage III 4 10
Stage IV 36 90
Bone metastasis 24 60
Site of bone metastasis
Pelvis 17 42.5
Skull 6 15
Ribs 17 42.5
Upper limbs 7 17.5
Lower limbs 9 22.5
Spinal column 17 42.5
Other 6 15
ITT ¼ intent to treat; TNM ¼ tumor, lymph node, distant metastasis.
Fig. 2. Testosterone concentrations at Days 0, 90, and 180.
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lakiuria, hematuria, urinary retention, urinary incontinence,
asthenia, and localization of pain) was reduced on Day 90 and
further reduced on Day 180 (Table 3). Sexual dysfunction
evaluation was only available for eight patients: one patient
reported sexual dysfunction that was resolved on Day 180.
At baseline, 24 (60%) of men had bone metastases, which
dropped to 23 (57.5%) patients by the end of the study. The
most frequently reported sites at the end of the study were the
same as baseline (pelvis, ribs and spinal column). Eight
patients (20%) developed new lesions during the study. One
patient had a complete response to the metastases lesion on his
spinal column by the end of study. Eight patients had newFig. 3. PSA concentrations at Days 0, 90, anlesions found during bone scintigraphy during the study, and
one patient had disease progression judged by clinical evalu-
ation giving a disease progression rate of 22.5% (95% CI:
10.84e38.45).
Treatment with triptorelin increased global health status
significantly from 59.58  24.72 at baseline to 66.46  17.24
at the end of the study (p < 0.05). All domains on the func-
tional scale (such as physical functioning, role functioning,
emotional functioning, cognitive functioning, and social
functioning) increased. Patients showed a decrease in score of
most domains on the symptom scale (that is, a decrease in
symptoms), with the results reaching significance for fatigue,
pain and appetite loss (p < 0.05).d 180. PSA ¼ prostate-specific antigen.
Table 3
Effect of treatment with Triptorelin on clinical symptoms after 90 and 180
days.
Symptom Evaluable patients (n ¼ 40)
Baseline Day 90 Day 180
Dysuria 10 (25.0%) 5 (12.5%) 1 (2.5%)
Pollakiuria 9 (22.5%) 5 (12.5%) 3 (7.5%)
Hematuria 6 (15%) 2 (5.0%) 1 (2.5%)
Urinary retention 4 (10%) 1 (2.5%) 1 (2.5%)
Urinary incontinence 1 (2.5%) 0 (0%) 1 (2.5%)
Asthenia 4 (10%) 1 (2.5%) 0 (0.0%)
Localization of pain 13 (32.5%) 7 (17.5%) 5 (12.5%)
Evaluable for sexual function (n ¼ 8)
Sexual dysfunction 1 (12.5%) 1 (12.5%) 0 (0.0%)
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enced at least one adverse event during the 6-month study
period. The most frequently reported adverse events were
constipation (9.8%), diarrhea (7.3%), and dysuria (7.3%)
(Table 4). One patient had an allergic reaction that caused him
to drop out. Three other patients experienced serious adverse
events; in one of these men their disease progressed leading to
death. The patient that died had extremely low PSA (0.05 ng/
mL) and testosterone (0.23 ng/mL) levels.3.6. TolerabilityIn general, triptorelin was well tolerated. On Day 90
patients reported the following: hot flushes (n ¼ 2; 4.9%);
decrease of libido (n ¼ 2; 4.9%); impotence (n ¼ 3; 7.3%);
gastric pain (n ¼ 1; 2.4%); and nausea (n ¼ 1; 2.4%). At the
end of the study patients reported decrease of libido (n ¼ 2;
4.9%), impotence (n ¼ 3; 7.3%), and transient and spontane-
ously resolving high blood pressure (n ¼ 1; 2.4%).3.7. Laboratory testsPlatelets, overall white blood cell, monocyte and basophil
count were reduced significantly by the end of the studyTable 4
Treatment-emergent adverse events.
Event Evaluated patients (n ¼ 41)
Overall Severity
Mild Moderate Severe
Any adverse event 25 (61.0%) 14 8 3
Constipation 4 (9.8%) 2 2 0
Diarrhea 3 (7.3%) 1 2 0
Dysuria 3 (7.3%) 2 1 0
Conjunctivitis 2 (4.9%) 2 0 0
Urinary tract infection 2 (4.9%) 2 0 0
Liver function test abnormal 2 (4.9%) 1 1 0
Insomnia 2 (4.9%) 2 0 0
Hematuria 2 (4.9%) 1 1 0
Nocturia 2 (4.9%) 2 0 0
Cough 2 (4.9%) 2 0 0
Dermatitis (contact) 2 (4.9%) 2 0 0
Pruritus 2 (4.9%) 2 0 0( p < 0.05). Significant changes were also seen in phosphate,
uric acid, and ALT. All of these changes were minor and none
was clinically significant.
4. Discussion
In this study, we showed that the sustained release formu-
lation of triptorelin 11.25 mg was effective in reducing
testosterone and PSA levels significantly, as well as reducing
clinical symptoms. One patient had a complete response at the
end of the study. Treatment with triptorelin also resulted in
improvement of quality of life scores, with significant
improvement in emotional functioning pain and appetite loss.
During the study nine patients developed new lesions, giving
a progression rate of 22.5%.
The most commonly seen adverse event was gastrointes-
tinal disturbance including abdominal pain, diarrhea and
constipation, which did not need medication and recovered
spontaneously. The withdrawal rate as a result of adverse
events was 2.5%; this included one patient who had allergic
reaction that caused him to drop out of the study. It is not know
whether the reaction was caused by triptorelin. Triptorelin,
like all GnRH agonists, acts by initially stimulating the pitu-
itary cells to release follicle-stimulating hormone and lutei-
nizing hormone, but chronic use desensitizes the pituitary
GnRH, resulting in the shutdown of LH and FSH production
and the suppression of testosterone production in the testes.
Hormone therapy for prostate cancer results in regression,
improvement in bone pain, lower urinary tract symptoms and
quality of life.20 For registration studies GnRH inhibitors are
required to achieve a serum testosterone level of 0.5 ng/mL,
a castration level of testosterone on Day 29, and to maintain
castration concentrations while on long-term therapy. The
reduction in and maintenance of castration concentrations of
testosterone on Day 180 triptorelin in this study confirms the
efficacy of triptorelin in Taiwanese men.
Serum PSA concentrations are used to measure disease
progression in prostate cancer. In this study triptorelin reduced
PSA by over 99% in men with prostate cancer, suggesting
disease regression. Indeed a disease progression rate of 22.5%
was seen. Eight patients developed new bone lesions during
the study. The survival rate was 97.5% within the six-month
period of this study. Because of the shortness of the study, it
is not possible to compare survival, or time to treatment failure
with other studies in the literature. However triptorelin has
previously been shown to have a nine-month survival rate of
97%, significantly higher than leuprolide with a survival rate
of 90.5%.20 Triptorelin may also more reliably maintain
castration concentrations of testosterone than leuprolide.20
In conclusion, triptorelin 11.25 mg is effective in
decreasing and maintaining serum testosterone to castration
level for a period of three months. Significant reduction of
serum PSA levels was also seen in most patients, suggesting
that their disease is under control. Adverse events were mild
and self-limiting, except for one patient who had serious
allergic reaction. In conclusion, triptorelin 11.25 mg is an
effective, and convenient GnRH agonist for the treatment of
261C.-C. Kao et al. / Journal of the Chinese Medical Association 75 (2012) 255e261advanced and metastatic prostate cancer with a good safety
and tolerability profile.
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